Cagrilintide and CagriSema: what amylin adds to semaglutide
Reviewed 20 sourcesPublished by PepVault
Cagrilintide is a weekly amylin drug, not a GLP-1. What it did alone, what it added to semaglutide in CagriSema's trials, the side effects and FDA status.

- Last reviewed
- Sources
- 20
- Questions
- 7
- Compounds
- 4
The short answer
Cagrilintide is a weekly, long-acting version of amylin, a fullness hormone the pancreas releases with insulin; it is not a GLP-1. On its own it cut weight by 6 to 12% in trials. Paired with semaglutide as CagriSema, it added about 6.6 points for people who stayed on treatment: 22.7% against 16.1% on semaglutide alone at 68 weeks. As of November 20, 2026, neither is FDA approved.
- Amylin is made with insulin and slows the stomach, holds down glucagon and brings fullness on sooner.
- Cagrilintide alone: 6.0% to 10.8% weight loss at 26 weeks, 11.8% at 68 weeks while on treatment.
- CagriSema beat semaglutide alone in REDEFINE 1 (22.7% against 16.1%) and REDEFINE 5 (18.4% against 11.9%); on blood sugar the gain is small.
- Not FDA approved as of November 20, 2026: filed December 18, 2025, with a US launch planned for early 2027 if approved.
Evidence: Phase 2 and phase 3 randomized trials in people, all funded by Novo Nordisk; as of November 2026 CagriSema is under FDA review and cagrilintide alone is in phase 3, so neither has a label.

What is amylin, and what does it do?
Amylin is a hormone made by the same pancreas cells that make insulin. The two are packed together and released together when you eat, and in type 1 and type 2 diabetes both fall1. After a meal amylin does three jobs: it slows how fast the stomach empties, it holds down glucagon (the hormone that pushes blood sugar up), and it acts on fullness, so people eat less1.
The first drug built on it was pramlintide (Symlin), approved by the FDA on March 16, 2005, as an add-on for people with diabetes who use mealtime insulin12. It is human amylin with three of its 37 amino acids swapped for proline1. Natural amylin tends to clump into fibers, which makes it a hard molecule to turn into a medicine3. Pramlintide lasts about 48 minutes in the body, so it is injected right before each main meal, up to three times a day13. Drugs@FDA now lists every Symlin product as discontinued2.

Is cagrilintide a GLP-1?
No. Cagrilintide is an amylin analogue: a lab-made amylin built to last. Novo Nordisk's chemists made the molecule stable and attached a fatty-acid chain to make it long-acting3. In people its half-life, the time for the blood level to halve, measured 159 to 195 hours, about a week, so it is a once-weekly shot5. Semaglutide's half-life in the same trial was 145 to 165 hours, which is why the two fit in one weekly dose, and cagrilintide did not change semaglutide's levels5.
It also reaches wider than pramlintide. Amylin receptors are built from the calcitonin receptor plus a partner protein. Pramlintide switches on amylin receptors only; cagrilintide switches on amylin receptors and the calcitonin receptor itself4. That was measured in lab cells, not people, and the paper cites earlier data that drugs with this wider reach may work better for weight4.
Try it
How Cagrilintide builds up
An estimate from a half-life of about 7 days, one dose a week for four weeks. The shape of the level, not a measurement.
What did cagrilintide do on its own?
Its first large test was a phase 2 trial published in The Lancet in 2021: 906 adults with obesity or overweight and no diabetes, at 57 sites in ten countries, for 26 weeks6. They took weekly cagrilintide at one of five doses from 0.3 to 4.5 mg, daily liraglutide 3.0 mg (the GLP-1 drug in Saxenda), or placebo6.
Every dose beat placebo: weight fell 6.0% to 10.8% against 3.0%6. The top dose, 4.5 mg, also beat liraglutide, 10.8% against 9.0%6. Those numbers estimate the loss had everyone stayed on the drug; the paper found similar results counting everyone6.
The 68-week REDEFINE 1 trial then gave 302 people cagrilintide 2.4 mg alone, reached after 16 weeks of dose steps718. They lost 11.8% on treatment, against 2.3% on placebo9; Novo Nordisk's announcement adds 11.5% counting everyone, against 3.0%8. By Novo's count it was the arm where most people stayed at full dose: 82.5% were on 2.4 mg at week 68, against 70.2% on semaglutide alone8. On its own, then, cagrilintide landed above liraglutide and below semaglutide.
How much does amylin add to semaglutide?
REDEFINE 1 was built to show it. It gave 3,417 adults without diabetes the pair (CagriSema, 2.4 mg of each), semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone or placebo for 68 weeks, in a ratio of 21:3:3:77. Its main test was the pair against placebo; the single-drug arms show what each half brings78.
Trials count weight loss two ways. On treatment estimates the loss had everyone stayed on the drug. Everyone counts every person randomized, including those who stopped, so it runs a little lower. Each row below is one trial; compare the columns within a row, not rows with each other, because the trials differ in who took part, how long they ran and how they counted.
| Trial (who, length, how counted) | CagriSema | Semaglutide alone | Cagrilintide alone | Placebo |
|---|---|---|---|---|
| REDEFINE 1, no diabetes, 68 weeks, on treatment89 | −22.7% | −16.1% | −11.8% | −2.3% |
| REDEFINE 1, the same trial, everyone; single-drug arms from Novo78 | −20.4% | −14.9% | −11.5% | −3.0% |
| REDEFINE 5, Japan and Taiwan, 68 weeks, on treatment11 | −18.4% | −11.9% | Not in trial | Not in trial |
| REDEFINE 2, type 2 diabetes, 68 weeks, everyone10 | −13.7% | Not in trial | Not in trial | −3.4% |
| REDEFINE 9, 1.0 or 1.7 mg of each, 68 weeks, on treatment13 | −21.0% (1.0 mg), −20.7% (1.7 mg) | Not in trial | Not in trial | −2.0% |
| Phase 2, 92 people with type 2 diabetes, 32 weeks12 | −15.6% | −5.1% | −8.1% | Not in trial |
| Phase 2, cagrilintide alone, 26 weeks, on treatment6 | Not in trial | Not in trial | −6.0% to −10.8% | −3.0% |
Read REDEFINE 1 across: amylin added 6.6 percentage points to semaglutide on treatment (22.7% against 16.1%)9, and 5.5 points counting everyone (20.4% against 14.9%) by Novo's figures8. Novo's announcement puts the biggest change at the deep end: 40.4% on the pair lost a quarter or more of their body weight, against 16.2% on semaglutide alone and 6.0% on cagrilintide alone8. The pair did this with fewer people at full dose. REDEFINE 1 let people stay on a lower step, and only 57.3% on CagriSema were on 2.4 mg of each at the end8.
REDEFINE 5 made the pair against semaglutide its main question, double-blind, and the gap held at 6.5 percentage points11. In a separate trial, REDEFINE 9, the lower doses of 1.0 mg and 1.7 mg of each brought about 21% on treatment at 68 weeks13. How the pair compares with tirzepatide (Zepbound) is its own guide.
On blood sugar, amylin adds less. In REIMAGINE 2, 2,713 adults with type 2 diabetes, double-blind for 68 weeks, HbA1c (the three-month blood sugar average) fell 1.91 points on the pair against 1.75 on semaglutide alone, a small but real gap20. In the 32-week phase 2 trial the gap, 2.2 against 1.8 points, was too small to be sure of12.
PepVault's weight log charts every weigh-in week by week, so you can read your own curve against the trial numbers above. Track your weight in PepVault
What side effects does CagriSema cause?
Mostly stomach effects, mostly early, mostly mild to moderate. In REDEFINE 1, 79.6% on the pair had a stomach or gut side effect at some point in the 68 weeks, against 39.9% on placebo, and most passed7; nausea led the list at 55% (12.6% on placebo), and 5.9% stopped over side effects, against 3.5%14.
Against semaglutide alone, amylin added little to the stomach load. In REDEFINE 5, 53% on the pair and 51% on semaglutide had a gut side effect, and 10% and 6% stopped treatment for any reason11. Cagrilintide alone, in its phase 2 trial, brought gut side effects to 41% to 63% across doses against 32% on placebo, mainly nausea (20% to 47% against 18%), with injection-site reactions among the most frequent events6.
Commonly reported: feeling full a few bites into a meal and portions shrinking without effort, with nausea or constipation in the days after a dose step that eases once the dose holds.
CagriSema has no label yet. Its semaglutide half carries Wegovy's warnings, including a boxed warning for thyroid C-cell tumors seen in rodents and a rule against use with a personal or family history of medullary thyroid cancer or MEN 217.
When to get help Stomach pain that is severe or will not go away, sometimes reaching through to the back, with or without vomiting, is the semaglutide label's sign of possible pancreatitis and a reason to contact your clinician promptly17.
PepVault logs side effects by day next to your dose log, so you can see whether nausea settles after a step-up. Log it in PepVault
Is cagrilintide or CagriSema FDA approved?
Not as of November 20, 2026. Drugs@FDA has no product containing cagrilintide19. Novo Nordisk submitted CagriSema (2.4 mg of each, once weekly) to the FDA on December 18, 2025, for weight loss in adults with obesity, or with overweight and at least one weight-related condition14. Its November 4, 2026 report puts the US decision in the fourth quarter of 2026 and says Novo is "preparing for the US launch of CagriSema in early 2027, subject to regulatory approval"15. Our CagriSema decision guide follows the review clock.
Cagrilintide on its own is a step behind. Its own phase 3 program, RENEW, is running: RENEW 1 gives about 300 adults with overweight or obesity weekly cagrilintide or placebo for 64 weeks16. The registry estimates its primary completion for May 2027, and Novo's milestone table puts RENEW 1 and 2 results in the second half of 20271516. Until a label exists, every dose quoted for either drug is a trial dose: REDEFINE 1 reached 2.4 mg after 16 weeks of steps, and the phase 2 trial tested 0.3 to 4.5 mg618.
CagriSema and cagrilintide are in PepVault's library: set the weekly shot day once, get a reminder each week, and every dose you log stays in your history. Set reminders in PepVault
What other amylin drugs are in trials?
Cagrilintide is not the only long-acting amylin drug. Eloralintide, petrelintide and amycretin are the next wave, each built differently, and all are still in trials. Cagrilintide's own phase 3 readout, RENEW 1, has a guide of its own.
Sources
- Symlin (pramlintide acetate) prescribing information, AstraZeneca. DailyMed, SPL version 18, effective December 18, 2019. dailymed.nlm.nih.gov
- Drugs@FDA: NDA 021332, Symlin (pramlintide acetate); original approval March 16, 2005; all products listed as discontinued (read November 20, 2026). accessdata.fda.gov
- Kruse T et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183-11194. PubMed 34288673
- Fletcher MM et al. AM833 is a novel agonist of calcitonin family G protein-coupled receptors. J Pharmacol Exp Ther. 2021;377(3):417-440. PubMed 33727283
- Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397:1736-1748. PubMed 33894838
- Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. PubMed 34798060
- Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635-647. PubMed 40544433
- Novo Nordisk company announcement No 99/2024: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial. December 20, 2024 (Form 6-K, SEC EDGAR). sec.gov
- Busetto L et al. Efficacy of CagriSema for reaching anthropometric treatment targets and cardiometabolic outcomes: a secondary, post hoc analysis of REDEFINE 1. Diabetes Obes Metab. 2026;28(10):9317-9325. PubMed 42503495
- Davies MJ et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). N Engl J Med. 2025;393(7):648-659. PubMed 40544432
- Yamauchi T et al. Co-administered cagrilintide and semaglutide versus semaglutide alone in adults in Japan and Taiwan (REDEFINE 5): a phase 3a trial. Lancet Diabetes Endocrinol. 2026;14(6):450-462. PubMed 42009015
- Frias JP et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a phase 2 trial. Lancet. 2023;402(10403):720-730. PubMed 37364590
- Wharton S et al. Co-administered cagrilintide-semaglutide 1.7 mg each and 1.0 mg each in adults with overweight or obesity (REDEFINE 9): a phase 3b trial. Lancet Diabetes Endocrinol. Published online November 14, 2026. PubMed 43033821
- Novo Nordisk: CagriSema submitted to the US FDA for weight management. Company announcement, December 18, 2025. novonordisk.com
- Novo Nordisk financial report for the first nine months of 2026. November 4, 2026 (Form 6-K, SEC EDGAR). sec.gov
- ClinicalTrials.gov NCT07220642 (RENEW 1): Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity. Novo Nordisk (read November 20, 2026). clinicaltrials.gov
- Wegovy (semaglutide) prescribing information, Novo Nordisk. DailyMed, SPL version 19, effective June 18, 2026. dailymed.nlm.nih.gov
- ClinicalTrials.gov NCT05567796 (REDEFINE 1): arms and dose-escalation period. Novo Nordisk (read November 20, 2026). clinicaltrials.gov
- openFDA Drugs@FDA query for the active ingredient cagrilintide: no matches (read November 20, 2026). api.fda.gov
- Buse JB et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026;14(8):662-677. PubMed 42251859
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.